KindlyMD, Inc. (NASDAQ:NAKA) Receives $22.33 Average Target Price from Brokerages

Shares of KindlyMD, Inc. (NASDAQ:NAKA) have received an average recommendation of “Hold” from the five brokerages that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $22.3333.

Several analysts have recently issued reports on NAKA shares. TD Cowen upped their target price on shares of KindlyMD from $1.00 to $17.00 and gave the company a “buy” rating in a research report on Monday, July 27th. Wall Street Zen upgraded KindlyMD to a “sell” rating in a research report on Saturday, May 23rd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of KindlyMD in a research note on Friday, August 7th.

KindlyMD Stock Performance

NAKA stock opened at $6.06 on Thursday. The firm has a fifty day moving average price of $4.45 and a 200 day moving average price of $7.29. KindlyMD has a fifty-two week low of $3.33 and a fifty-two week high of $432.40. The firm has a market cap of $108.47 million, a PE ratio of -0.17 and a beta of 15.95.

KindlyMD (NASDAQ:NAKA) last released its quarterly earnings results on Thursday, August 13th. The company reported ($6.65) earnings per share (EPS) for the quarter. KindlyMD had a negative net margin of 1,067.93% and a negative return on equity of 63.45%. The business had revenue of $35.87 million for the quarter. On average, equities analysts predict that KindlyMD will post -16.8 EPS for the current year.

Insider Activity

In related news, CEO David F. Bailey bought 55,115 shares of the company’s stock in a transaction dated Thursday, May 28th. The stock was purchased at an average price of $5.62 per share, for a total transaction of $309,746.30. Following the acquisition, the chief executive officer owned 3,175,476 shares in the company, valued at $17,846,175.12. This trade represents a 1.77% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last three months, insiders purchased 191,448 shares of company stock valued at $992,908. 24.49% of the stock is owned by company insiders.

Institutional Trading of KindlyMD

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Alyeska Investment Group L.P. purchased a new position in KindlyMD during the fourth quarter worth $8,993,000. ParaFi Capital LP purchased a new stake in shares of KindlyMD in the third quarter valued at $443,055,000. Hunting Hill Global Capital LLC bought a new stake in shares of KindlyMD in the 4th quarter worth about $4,672,000. Yorkville Advisors Global LP bought a new stake in shares of KindlyMD in the 4th quarter worth about $3,265,000. Finally, UBS Group AG purchased a new position in shares of KindlyMD during the 4th quarter worth about $2,958,000.

About KindlyMD

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.